THE PHARMACEUTICAL RESEARCH DIARIES

Antibody avidity meets various myeloma In the continued look for impressive treatment options to beat refractory and relapsed cancer, new preclinical get the job done in multiple myeloma displays that raising binding avidity by concentrating on two antigens in a single T cell-partaking trispecific antibody boosts anti-tumor activity and lowers the